TScan Therapeutics Inc (TCRX)

[FACT-MASTER]

TCRX financing news:

https://finance.yahoo.com/news/tscan-therapeutics-announces-pricing-140-043700771.html

Haven't had time to do dd on pre-funded warrants etc,

Let's see how much of the over-allotment the underwriters subscribe for.

[FACT-MASTER]

No, but there could be merit in using the (TCR) approach in a select population of patients who unable to undergo an HSCT.

In AML that would be patients at a high risk of relapse, as defined by CR following induction, but are MRD+, and/or with incomplete recovery of neutrophil (CRi) or platelet counts (CRp). In that group more than 80% will relapse within the first year no matter what is (currently) done after induction therapy https://ascopubs.org/doi/full/10.1200/JCO.2014.58.3518

The wisdom of your response above, is duly understood.

The prognosis for the condition you have outlined above is very poor, ( lost a friend and business colleague to pretty much exactly this condition in 2022).


One factor that i've thought about though, is the possibility of a "mutational footprint " left by some induction therapies and if that would effect the TScan tech. From the recent display of data, it doesn't appear to be an issue.

The other articles you posted are highly informative, imo - still reading

[The Night Stalker]

dip

[The Night Stalker]

yeah, got like 50 biotechs on my watchlist, powerful volume this month,, what is cash position to fund future operations etc all that bs gay stuff


https://www.stockscores.com/charts/charts/?ticker=tcrx

[jondoeuk]

No, but there could be merit in using the (TCR) approach in a select population of patients who unable to undergo an HSCT.

In AML that would be patients at a high risk of relapse, as defined by CR following induction, but are MRD+, and/or with incomplete recovery of neutrophil (CRi) or platelet counts (CRp). In that group more than 80% will relapse within the first year no matter what is (currently) done after induction therapy https://ascopubs.org/doi/full/10.1200/JCO.2014.58.3518

I also know of a PhI/II trial testing auto CD8+ (central memory vs. naïve phenotype) T-cells transduced using a viral vector to target WT1. Of seven treated, four are NED, with the other three relapsing. There are data from two (the third declined additional treatment before passing away) showing one was due to WT1 negative disease and the other was due to failure of T-cells.

WT1 is an oncogene and also expressed on leukemic stem cells https://www.nature.com/articles/nature22993

Looking at the patient who was WT1 negative, their disease was found to express CCNA1, so could be targeted with a different TCR https://ashpublications.org/bloodadvances/article/4/2/387/440610/Evaluation-of-cyclin-A1-specific-T-cells-as-a

As for the second, immunosuppressive and rapid proliferation of the disease were likely the reason, so other modifications to T-cells will be needed to address both, such as this https://ashpublications.org/blood/article/130/22/2410/36564/A-CD200R-CD28-fusion-protein-appropriates-an

[The Night Stalker]

red

[crazy horse 0]

I moved over to VIRI check it out

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_05162023_VIRI_Bautz.pdf

[FACT-MASTER]

The short interest doesn't appear to be of any concern, so no squeeze, imo.

The Finra dark pool data is of concern. From whence these shares became, and traded between whom, and for what purpose? - are all questions that come to mind. And suggests shares outstanding may now be higher. This wouldn't surprise as i recall an offering a while back atm - i'll see if i can find that.

Markets are strange sometimes.
imo, the recent data is awesome, and the hope for the cancer patient has never looked better. The Tscan approach is highly sophisticated, imo, and if positive data continues, somehow i would hope this remains USA technology.

Thanks for the post and link.
I'll continue to be long term here at TCRX and not concerned about the present price spasms.

[crazy horse 0]

Shares Outstanding 24.23M
Shares Float 17.61M
Institutional Ownership 63.50%
Short Float 0.51%

https://www.shortablestocks.com/?TCRX

[crazy horse 0]

They are having a Replay you could listen it was all positive IMO looking to end of 2023 for another milestone

Did anybody ask about the far right 3 slides here:(re TSC101)

https://www.tscan.com/wp-content/uploads/2023/05/ASGCT-poster-2023.pdf

in relation to Slide 44 of the May TCRX Corporate presentation here, where they use the word "CURE"

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Thank you in advance.

[FACT-MASTER]

Would there be any merit to TCRX utilizing TSC100/TSC101 pre HCT? (ie as new SOC)/
Would that probably require study change / FDA approval?

Thank you in advance.

[FACT-MASTER]

Did anybody ask about the far right 3 slides here:(re TSC101)

https://www.tscan.com/wp-content/uploads/2023/05/ASGCT-poster-2023.pdf

in relation to Slide 44 of the May TCRX Corporate presentation here, where they use the word "CURE"

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Thank you in advance.

[FACT-MASTER]

Good to hear, I would have loved to attended- just couldn't get away.

Was there much discussion on the TSC101 CD4*CD8* part of the trial.

From the poster presentation this looks most interesting ( far right slides - TSC101 CD4*CD*/ UD Chimerism/ TP53

https://www.tscan.com/wp-content/uploads/2023/05/ASGCT-poster-2023.pdf

[crazy horse 0]

Key Poster Highlights:

Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting MiHAs HA-1 and HA-2, respectively, to treat residual disease and prevent relapse following HCT using RIC in patients with AML, MDS or ALL

Two control arm patients have been enrolled and received standard of care (SOC) (HCT alone):

Both control arm patients have medium-risk MDS and experienced incomplete donor chimerism (presence of patient-derived cells) following transplant
One patient is now in early stages of relapse: after 100 days, patient-derived cells are still observed and increasing
TSC-101 treatment arm (n=1 high-risk MDS with p53 mutation):

DL1 administered 21 days after transplant Engineered T cells showed expansion between 14-21 days after infusionDetectable markers of activation and proliferation observed
Twenty-one days after treatment and 42 days after transplant, donor chimerism was at 100% (no detectable patient-derived hematopoietic cells with sensitivity limit of 0.13%)
Minimal residual disease (MRD) assessment: p53 mutation was not detected post-transplant in bone marrow and peripheral blood samples, with sensitivity limit of 0.01%
No DLTs observed
Study advancing to DL2
TSC-100 treatment arm (n=1 T-cell ALL):

DL1 administered 28 days after transplant
T cell expansion occurred on Day 7 with detectable markers of T cell activation and proliferation
Two assays are used to detect the action of T cells:

MRD: SOC assays measuring remaining malignant cells use flow cytometry, which has a sensitivity of ~0.1% High sensitivity assay based on next-generation sequencing (NGS) and droplet digital PCR is also used in this study, with a sensitivity of 0.01%
Chimerism: SOC STR assays have ~1% sensitivity Study is using the high-sensitivity NGS-based Alloheme assay, with a sensitivity of ~0.13%
A copy of the poster can be accessed on the “Publications” section of the Company’s website at www.tscan.com.

https://www.otcmarkets.com/stock/TCRX/news/story?e&id=2531529

[crazy horse 0]

Very Good TCRX Presentation well run and informational from all involved

[crazy horse 0]

Meeting is in one Hour I signed in

[jondoeuk]

The poster https://www.tscan.com/wp-content/uploads/2023/05/ASGCT-poster-2023.pdf

PR https://www.globenewswire.com/news-release/2023/05/17/2670856/0/en/TScan-Therapeutics-Presents-Preliminary-Phase-1-Clinical-Results-on-TSC-100-and-TSC-101-at-the-American-Society-of-Gene-Cell-Therapy-26th-Annual-Meeting.html

[crazy horse 0]

FORM 8-K

https://www.otcmarkets.com/filing/html?id=16661607&guid=rMu-kFBCz95eJth

[crazy horse 0]

NEWS TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation

https://www.otcmarkets.com/stock/TCRX/news/story?e&id=2531529

Company to host a virtual KOL event featuring Monzr M. Al Malki, M.D., to discuss highlights from the meeting and preliminary data today, Wednesday, May 17th at 5:30 p.m. ET

WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigens (MiHA) HA-1 and HA-2, respectively, to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) using reduced intensity conditioning (RIC) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting 2023.

TScan has developed two lead TCR-T cell therapy candidates, TSC-100 and TSC-101, that express TCRs targeting MiHAs HA-1 and HA-2, respectively, both presented by HLA-A*02:01. The goal is to select HCT patients who are HA-1 or HA-2 positive, with donors who are mismatched on either the MiHA or HLA-A*02:01. In this context, TSC-100 and TSC-101 are designed to eliminate all recipient hematopoietic cells, including malignant cells, that persist post-transplant, while leaving donor-derived cells unaffected. Both products are being developed in patients with AML, ALL, and MDS undergoing allogeneic haploidentical HCT with RIC, with the goal of preventing disease relapse. Approximately 42% of patients with these diseases relapse within two years of RIC transplant, at which point there are limited treatment options and poor prognosis. The longer-term objective is to enable more patients to maintain prolonged remission after receiving HCT with RIC, which is a more tolerable conditioning regimen than myeloablative conditioning.

“We continue to make meaningful progress in our Phase 1 umbrella trial with preliminary data presented at ASGCT demonstrating notable differences following treatment with both of our TCR-T cell therapy candidates,” said Debora Barton, M.D., Chief Medical Officer. “In a p53-mutated MDS patient who received TSC-101 infusion, we observed T cell expansion between 14 and 21 days post-treatment and observed markers of T cell activation and proliferation. Particularly encouraging, this patient had 100% donor chimerism post-transplant with no detectable patient-derived hematopoietic cells with sensitivity limit of 0.13%, and no dose-limiting toxicities. Our Phase 1 study is rapidly enrolling and TSC-101 is advancing into the second dose level. We are on track to reach the recommended Phase 2 dose for TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023.”

Gavin MacBeath, Ph.D., acting Chief Executive Officer and Chief Scientific and Operating Officer added: “We are very excited to progress to the second dose level for TSC-101 after seeing encouraging results from the patient at this first dose level. We are hopeful to continue to produce robust clinical outcomes as we progress our Phase 1 trial and remain excited about the potential clinical benefits our engineered T cells may have in difficult-to-treat patient populations.”

The Phase 1 umbrella trial is a multi-arm, i3+3 study evaluating TSC-100, TSC-101, and standard of care HCT alone (control arm) in patients with AML, ALL or MDS. Patients enrolled in Dose Level 1 (DL1) receive either TSC-100 or TSC-101 upon count recovery after HCT at approximately day 21. Patients enrolled in Dose Level 2 (DL2) will receive the same dose of TSC-100 or TSC-101 approximately 21 days post-transplant, followed by a second dose administered 40 days after the initial dose, provided there are no safety issues. The trial design also includes a third dose level (DL3), where the second dose is escalated 4-fold.

Key Poster Highlights:

Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting MiHAs HA-1 and HA-2, respectively, to treat residual disease and prevent relapse following HCT using RIC in patients with AML, MDS or ALL

Two control arm patients have been enrolled and received standard of care (SOC) (HCT alone):

Both control arm patients have medium-risk MDS and experienced incomplete donor chimerism (presence of patient-derived cells) following transplant
One patient is now in early stages of relapse: after 100 days, patient-derived cells are still observed and increasing
TSC-101 treatment arm (n=1 high-risk MDS with p53 mutation):

DL1 administered 21 days after transplant Engineered T cells showed expansion between 14-21 days after infusionDetectable markers of activation and proliferation observed
Twenty-one days after treatment and 42 days after transplant, donor chimerism was at 100% (no detectable patient-derived hematopoietic cells with sensitivity limit of 0.13%)
Minimal residual disease (MRD) assessment: p53 mutation was not detected post-transplant in bone marrow and peripheral blood samples, with sensitivity limit of 0.01%
No DLTs observed
Study advancing to DL2
TSC-100 treatment arm (n=1 T-cell ALL):

DL1 administered 28 days after transplant
T cell expansion occurred on Day 7 with detectable markers of T cell activation and proliferation
Two assays are used to detect the action of T cells:

MRD: SOC assays measuring remaining malignant cells use flow cytometry, which has a sensitivity of ~0.1% High sensitivity assay based on next-generation sequencing (NGS) and droplet digital PCR is also used in this study, with a sensitivity of 0.01%
Chimerism: SOC STR assays have ~1% sensitivity Study is using the high-sensitivity NGS-based Alloheme assay, with a sensitivity of ~0.13%
A copy of the poster can be accessed on the “Publications” section of the Company’s website at www.tscan.com.

Virtual KOL Event

The Company will share highlights from its poster presented at ASGCT, featuring Monzer M. Al Malki, M.D, Associate Profession, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, on Wednesday, May 17th at 5:30 p.m. ET to discuss the presentation and results from the ongoing Phase 1 study of TSC-100 and TSC-101 to treat residual disease and prevent relapse following HCT using RIC in patients with AML, MDS and ALL. To register for the event, please click here. A replay will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company’s plans, progress, and timing relating to the Company’s hematologic malignancies program, including patient enrollment, reaching recommended Phase 2 dose for TSC-100 and TSC-101, and interim clinical data; the structure, timing and success of the Company’s planned preclinical development and clinical trials; the potential benefits of any of the Company’s proprietary platforms, multiplexing, or current or future product candidates in treating patients; and the Company’s goals, focus, and strategy. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, “may,” “might,” “advance,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan’s TCR-T therapy candidates; TScan’s expectations regarding its preclinical studies being predictive of clinical trial results; TScan’s approved INDs and enrollment of patients in its study being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the partnership with Amgen being indicative or predictive of the value of TScan’s target discovery platform outside of oncology; the timing of the launch, initiation, progress and expected results and announcements of TScan’s preclinical studies, clinical trials and its research and development programs; TScan’s timeline regarding its filing of INDs for its TCRs throughout the year, TScan’s ability to enroll patients for its clinical trials within its expected timeline, TScan’s plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan’s TCR-T therapy candidates; TScan’s manufacturing capabilities and the scalable nature of its manufacturing process; TScan’s estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan’s expectations regarding competition; TScan’s anticipated growth strategies; TScan’s ability to attract or retain key personnel; TScan’s ability to establish and maintain development partnerships and collaborations; TScan’s expectations regarding federal, state and foreign regulatory requirements; TScan’s ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan’s existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Contacts

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
[e-mail]

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
[e-mail]

https://www.globenewswire.com/newsroom/ti?nf=ODg0MDk5MiM1NTk5ODcwIzIyMDcwNjk=
https://ml.globenewswire.com/media/ZWIwMjMxNTMtZmI3My00MzI0LTk0ZjMtODMyMWMwZDFjODAwLTEyMTg2MjI=/tiny/TScan-Therapeutics-Inc-.png

Source: TScan Therapeutics, Inc.
© 2023 GlobeNewswire, Inc.

Got a View on the Market?
Sponsored By : Cboe Global Markets, Inc.
Whether trading large contracts (SPX®) or mini (XSP?), S&P 500® Options let you to trade short or long and adapt quickly to volatility.

[crazy horse 0]

AW 1 d419056daw.htm AW TSCAN THERAPEUTICS, INC. May 16, 2023

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F. Street N.E.

Washington, D.C. 20549



Re:
TScan Therapeutics, Inc. (CIK 0001783328)

Request to Withdraw Pre-Effective Amendment No. 1 to Registration Statement (Reg No. 333-268260) on Form S-3 (Accession No. 0001193125-23-145261)

Ladies and Gentlemen:

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), TScan Therapeutics, Inc. (the “Company”) hereby requests the immediate withdrawal of the Company’s Amendment No. 1 to Registration Statement on Form S-3 referred to above (the “Amendment”), which was filed on May 16, 2023, together with all exhibits thereto, with Accession No. 0001193125-23-145261. No securities were sold pursuant to this Amendment.

Two Amendments No. 1 to the Registration Statement on Form S-3 were filed under the EDGAR submission header for Reg No. 333-268260.

The Company is requesting the immediate withdrawal of the Amendment No. 1 that references Reg. No. 333-268261 (Accession No. 0001193125-23-145261).

The Company is not seeking the withdrawal of the Amendment No. 1 that references Reg. No. 333-268260 (Accession No. 0001193125-23-145259).

Thank you for your assistance in this matter. If you have questions regarding this request, please contact the Company’s legal counsel, William D. Collins, Esq., of Goodwin Procter LLP, at [phone].



Very truly yours,

/s/ Brian Silver

Chief Financial Officer


cc:
Zoran Zdraveski, Esq. (Chief Legal Officer at TScan Therapeutics, Inc.)

William D. Collins, Esq. (Goodwin Procter LLP)

David Li, Esq. (Goodwin Procter LLP)

Insight source

https://quantisnow.com/insight/4513795

[crazy horse 0]

$TCRX Amgen and Novartis are involved with TCRX enough said

https://www.otcmarkets.com/stock/TCRX/news/story?e&id=2522538

[crazy horse 0]

S-3/A Filings

https://www.otcmarkets.com/stock/TCRX/disclosure

[crazy horse 0]

Holy COW that is some presentation

TCRX May Corporate Presentation is a must read for serious investors

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

The whole presentation spells out the potential from oncology - autoimmune - infectious disease

Of course, it will be the trial data that will confirm whether the TCR-T approach is indeed successful.

Thank you.

[crazy horse 0]

Will listen to that Presentation if I am allowed in

TCRX May Presentation (it has been posted on TCRX website)

Awesome presentation coming up at ASGCT imo, - highly, highly professional, imo.
Gonna turn some heads on Wednesday, imo.

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Spot on again bro, Slide #7

TScan Therapeutics, Inc.
Steady value-generating data flow across clinical programs
Heme Program
Enroll patients in all 3 arms of trial
Safety and biomarker data at ASGCT

[The Night Stalker]

agreed

[FACT-MASTER]

TCRX May Corporate Presentation is a must read for serious investors

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

The whole presentation spells out the potential from oncology - autoimmune - infectious disease

Of course, it will be the trial data that will confirm whether the TCR-T approach is indeed successful.

Thank you.

[FACT-MASTER]

TCRX May Presentation (it has been posted on TCRX website)

Awesome presentation coming up at ASGCT imo, - highly, highly professional, imo.
Gonna turn some heads on Wednesday, imo.

https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

Spot on again bro, Slide #7

TScan Therapeutics, Inc.
Steady value-generating data flow across clinical programs
Heme Program
Enroll patients in all 3 arms of trial
Safety and biomarker data at ASGCT

[FACT-MASTER]

That looks like potential sales by David Southwell who stepped down on March 31/23.

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-announces-ceo-transition

Some shares bought on the open market and some for compensation, looks like the holding period requirement has been met.

https://www.upcounsel.com/rule-144

[crazy horse 0]

FORM 144 Title of the Class of Securities To Be Sold

https://www.otcmarkets.com/filing/html?id=16656101&guid=Hiu-kFUYuTxmB3h

#1 Common
Charles Schwab Company
3000 Schwab Way
Westlake
TEXAS
76262
85,911 $346,221.00 19,480,729 05/15/2023
Nasdaq

[crazy horse 0]

A Buyout is not out of the Question

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

On another topic, it appears that Amgen Oncology does not currently have a TCR-T Modality category in their pipeline.

see here:

https://www.amgenoncology.com/clinical-trial-finder.html#modality

then click on Oncolytic Immunotherapy

https://www.amgenoncology.com/modalities/oncolyticimmunotherapy.html

Physicians have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to harness this potential by using genetically modified viruses to target tumors in several important and complementary ways.1

By deleting certain genes, viruses can be reprogrammed to replicate in tumor cells but not in normal cells. This selective viral replication causes the tumor cells to lyse—releasing tumor-specific antigens.1 The virus can also be modified to produce human GM-CSF, signaling dendritic cells to the site of the lysed tumors where they encounter tumor antigens—generating a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant metastases throughout the body.

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

Click on Technology https://www.tscan.com/

[crazy horse 0]

And one of the Directors of Bakers Bros sits on the Board very positive

That's a nice update, thanks for posting that. Impressive institutional involvement, imo.

The category of TCR-T, is still relatively new imo, with little in vivo data available to date.

For information purposes, Kimmtrack was the first FDA approved TCR-T in January of 2022 and there is an interesting read here :

https://acgtfoundation.org/news/explaining-t-cell-receptor-therapy-for-cancer/

[FACT-MASTER]

On another topic, it appears that Amgen Oncology does not currently have a TCR-T Modality category in their pipeline.

see here:

https://www.amgenoncology.com/clinical-trial-finder.html#modality

then click on Oncolytic Immunotherapy

https://www.amgenoncology.com/modalities/oncolyticimmunotherapy.html

Physicians have long observed that certain viruses can slow the progression of cancer. Oncolytic immunotherapy aims to harness this potential by using genetically modified viruses to target tumors in several important and complementary ways.1

By deleting certain genes, viruses can be reprogrammed to replicate in tumor cells but not in normal cells. This selective viral replication causes the tumor cells to lyse—releasing tumor-specific antigens.1 The virus can also be modified to produce human GM-CSF, signaling dendritic cells to the site of the lysed tumors where they encounter tumor antigens—generating a broad immunotherapeutic response that can help cytotoxic T cells to recognize and attack distant metastases throughout the body.

(i'm not 100% sure, but TCRX Technology may be a perfect fit for Amgen Oncology and there could be more to the recent Amgen collaboration then Cohns disease, in my optimistic opinion.)

Click on Technology https://www.tscan.com/

[FACT-MASTER]

That's a nice update, thanks for posting that. Impressive institutional involvement, imo.

The category of TCR-T, is still relatively new imo, with little in vivo data available to date.

For information purposes, Kimmtrack was the first FDA approved TCR-T in January of 2022 and there is an interesting read here :

https://acgtfoundation.org/news/explaining-t-cell-receptor-therapy-for-cancer/

[crazy horse 0]

TScan is a clinical-stage biopharmaceutical company dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Very impressive Management and Board Members

https://www.tscan.com/

[crazy horse 0]

TCRX outstanding shares of 24,225,954,

As of March 31, 2023, the Company had issued and outstanding shares of 24,225,954, which consists of 19,480,729 shares of voting common stock and 4,745,225 shares of non-voting common stock.

https://ir.tscan.com/news-releases/news-release-details/tscan-therapeutics-reports-first-quarter-2023-financial-results/?auth_token=2aba5703-2c15-47d3-8454-aae1810f335b

[crazy horse 0]

BOARD OF DIRECTORS TCRX BAKER BROS. ADVISORS LP Stephen Biggar, M.D., Ph.D

Stephen Biggar, M.D., Ph.D., has served as a member of our board of directors since March 2021. Dr. Biggar is a partner at Baker Bros. Advisors LP, a biotechnology-focused investment advisor, a firm he joined in April 2000. Dr. Biggar serves on the boards of directors of Kiniksa Pharmaceuticals, Ltd., and Acadia Pharmaceuticals Inc.

Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.

.https://www.tscan.com/leader/stephen-biggar-m-d-ph-d/

[crazy horse 0]

TCRX institution holders

[FACT-MASTER]

TCRX: Novartis collaboration news (old news)

https://www.sec.gov/Archives/edgar/data/1783328/000095012321003678/filename3.htm

https://www.biospace.com/article/tscan-and-novartis-partner-to-develop-immune-therapies-for-solid-tumors/

https://www.biopharminternational.com/view/tscan-therapeutics-novartis-collaborate-t-cell-receptor-therapies

Collaboration period ended March 31/23 = 180 day countdown for Novartis to exercise licensing (Sept.28/23 deadline to advise on intent to license/Tscan notice of intent to license to third party)

[FACT-MASTER]

Novartis Collaboration:

https://ih.advfn.com/stock-market/NASDAQ/tscan-therapeutics-TCRX/stock-news/91014982/quarterly-report-10-q

"The Company will continue to assess the probability of milestone
payments throughout the180-day right of first negotiation period".

What insights are available into what TCRX might have discovered during the Novartis collaboration period, and to whom would these TCR targets be of concern/value to? And to what monetary value are such TCR discoveries worth/to Novartis/others.

Deadline for the 180-day right of first negotiation period, in and around September 28 by my count.

Given the Amgen news came out, out of nowhere, so to, could news on licensing/Novartis come out anytime to Sept.28/23.

[crazy horse 0]

TCRX Look at the pipelines and partners in $AMGN and $NVS. One of a kind!!!

[crazy horse 0]

May 17 EVENT, They halted TCRX IMO for Shorts to cover

TScan Therapeutics ASGCT Event: Highlights from Phase 1 Umbrella Trial of TSC-100 and TSC-101

https://lifescievents.com/event/tscan/

[ttottip]

Insiders know something. If so, the price will plunge drastically.

[ttottip]

Insiders know something.

[Gizzer211]

Offering?

[IOUBLOKE1]

halted

[crazy horse 0]

$TCRX TScan Therapeutics ASGCT Event: Highlights from Phase 1 Umbrella Trial of TSC-100 and TSC-101

https://lifescievents.com/event/tscan/

[Jess070283]

Adding. This is my biggest swinger into double digits!$$$

[dinogreeves]

This is buy, buy and hold: Main reason why I am here is Baker Bros.

[crazy horse 0]

TCRX Analysts have set a mean price target of 10.71. This target is 138% above the current price.

TCRX was analyzed by 11 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about TCRX.

In the previous month the buy percentage consensus was at a similar level.
TCRX was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.

2023-05-11 HC Wainwright & Co. Reiterate Buy -> Buy

https://www.chartmill.com/stock/quote/TCRX/analyst-ratings?utm_source=stocktwits&utm_medium=ANALYST&utm_content=TCRX&utm_campaign=social_tracking

[crazy horse 0]

TScan Therapeutics Inc "We're excited to apply our target discovery platform to the autoimmunity space," said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. "Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases."

Inflammatory bowel disease (IBD) is a term for two conditions – Crohn's disease and ulcerative colitis – that are characterized by chronic inflammation of the gastrointestinal tract.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube.

About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html

Multi-year partnership with AMGN https://www.prnewswire.com/news-releases/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease-301818552.html

Per the terms, TCRX will receive $30M upfront in addition to preclinical, clinical, regulatory, and commercial milestones worth over $500M and tiered single-digit royalties. "TScan's platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs," Raymond Deshaies, AMGN's SVP of Global Research, said.